Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system (Q38166600)

30 August 2017

title

Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system (English)

1 reference

30 August 2017

1 reference

Nikolaos Ioakeimidis

1

1 reference

30 August 2017

John B Kostis

series ordinal

2

1 reference

30 August 2017

publication date

25 November 2013

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

30 August 2017

published in

1 reference

30 August 2017

volume

19

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

53-64

1 reference

Erectile dysfunction and its association with metabolic syndrome and endothelial function among patients with type 2 diabetes mellitus

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Erectile dysfunction as a cardiovascular risk factor in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Erectile dysfunction and coronary disease: evaluating the link

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

The link between erectile and cardiovascular health: the canary in the coal mine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE i

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

The triad: erectile dysfunction--endothelial dysfunction--cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Anatomy, physiology, and pathophysiology of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Erectile dysfunction, depression, and ischemic heart disease: does the existence of one component of this triad necessitate inquiring the other two?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Expression, distribution and regulation of phosphodiesterase 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Cardiovascular effects of phosphodiesterase 5 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Overview of phosphodiesterase 5 inhibition in erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

PDE5 inhibitors: in vitro and in vivo pharmacological profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Cardiovascular risk, drugs and erectile function--a systematic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Antihypertensive treatment and sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Sildenafil for male erectile dysfunction: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Medical implications of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Duration of erectile dysfunction and its relationship to treatment seeking and satisfaction with treatment using PDE5 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Cardiovascular effects of phosphodiesterase type 5 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Cardiac uses of phosphodiesterase-5 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Erectile dysfunction in heart failure: correlation with severity, exercise performance, comorbidities, and heart failure treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Long-term use of sildenafil in the therapeutic management of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Cardiovascular risk among men seeking help for erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Anti-platelet therapy: phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Erectile dysfunction in the cardiovascular patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Welcome to the machine: a cardiologist's introduction to protein folding and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Erectile dysfunction as a complication of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Managing erectile dysfunction in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Sexual response in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Lifestyle management of erectile dysfunction: the role of cardiovascular and concomitant risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Lifestyle and metabolic approaches to maximizing erectile and vascular health

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413504034

21 January 2018

Identifiers

DOI

10.1177/1074248413504034

1 reference

30 August 2017

1 reference